Nimotuzumab in Combination With Radiochemotherapy for Patients With Stage IIIA/IIIB Non-small Cell Lung Cancer

Not Applicable

• Conditions: Non-small Cell Lung Cancer
• Interventions: Drug: nimotuzumab; Drug: Cisplatin; Drug: Etoposide; Radiation: radiotherapy

• Registration Number: NCT02549261
• Lead Sponsor: Biotech Pharmaceutical Co., Ltd.

Brief Summary

Nimotuzumab (hR3) is an IgG1 humanized monoclonal antibody that recognized an epitope located in the extra cellular domain of the human epidermal growth factor receptor (EGFR). Clinical efficacy has been shown in adult with head and neck cancer. The study assessed the efficacy and safety of the combination of Nimotuzumab administered concomitantly with chemoradiotherapy in patients with NSCLC .There is a tolerance trial of Nimotuzumab in Combination With Radiochemotherapy treatment before the randomization,double blind,muti-center sites trial of this treatment.

Detailed Description

There is a tolerance trial of Nimotuzumab in Combination With Radiochemotherapy treatment before the randomization,double blind,muti-center sites trial of this treatment.

Study Timeline

• Study Start: 2011-03
• Primary Completion: 2012-04
• Study First Submitted: 2015-08-18
• Status Verified: 2015-09
• Study First Submitted QC: 2015-09-11
• Last Update Submitted: 2015-09-11
• Study First Posted: 2015-09-15
• Last Update Posted: 2015-09-15
• Study Completion: 2015-12

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 150

Inclusion Criteria

1. Age from 18 to 70

2. both male and female

3. Subjects with pathologically or cytologically documented stage IIIB or IV NSCLC. Disease must be newly diagnosed.

4. Subjects would refer to the radical radiation therapy, but never have the previous chemotherapy or thoracic radiation therapy.

5. V20<30%, means that the percentage of the volume of lung which received the radiation<20Gy accounts the whole volume of lung is less than 30%.

6. Presence of at least 1 uni-dimensionally measurable index lesion,with the longest diameter ≥ 20 mm using conventional computer tomography(CT)/magnetic resonance imaging(MRI)scan or ≥ 10 mm using spiral computed tomography scan.

7. without pulmonary atelectasis, malignant pleural effusion malignant hydropericardium.

8. with ECOG performance status 0-2,and Life expectancy of more than 3 months.

9. without other malignancy history, except curative carcinoma in situ of cervix and skin basal cell carcinoma.

10. functions of major organs( haemogram,heart,liver,kidney)are basically normal, White blood count ≥3.5 x 109/L with neutrophils ≥1.5 x 109/L, platelet count≥100 x 109/L, and hemoglobin ≥90g/L.

    Total bilirubin ≤1.5 times upper limit of normal (ULN) range; alkaline phosphatase(ALP)≤ 2.5 times ULN, Transaminases AST (SGOT) and ALT (SGPT) ≤ 2.5 times ULN, serum creatinine ≤ 1.2 times ULN .

    pulmonary function, FEV1≥1L, and >40% normal value.

11. willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures.

12. both female and male patients must use adequate methods of contraception.

13. Signature of the informed consent

Exclusion Criteria

1. Previous radiotherapy, chemotherapy or anticancer biotherapy. Participation other clinical trials within 1 month prior to inclusion in the trial.
2. with the measureable lesion or lesion could be determined.
3. Severe diseases in lung, i.e. emphysema, interstitial pneumonia, bronchial asthma.
4. uncontrolled diabetes-random plasma glucose; RPG>11.1mmol/L.（RPG>11.1mmol/L, blood-fasting sugar; BFS; <7.8mmol/L，the patient also be enrolled）.
5. With other serious internal diseases or uncontrolled infection.
6. refractoriness dysentery or enterospasm, intestinal obstruction.
7. pregnancy, lactation, fertility but using a prohibited contraceptive method.
8. cardiovascular diseases history, congestive heart failure>GradeII, New York Heart Association (NYHA) criteria). With the unstable angina, de novo angina ( happened within 3 month prior to inclusion in the trial) or have myocardial in recently six months.
9. With drug addition, I.e. ,drug-taking, drug-taking for long time; type B hepatitis and C hepatitis in active stage, or with AIDS.
10. With organ transplantation,or using adrenocortical hormone or immunosuppressive agents for long time.
11. With history of serious allergic or allergy.
12. Not fit for the clinical trial judged by the investigator.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
the tolerance trial of treatment	radiotherapy	nimotuzumab,chemotherapy (Cisplatin+Etoposide),radiotherapy,9 pts
B	radiotherapy	chemotherapy (Cisplatin+Etoposide),radiotherapy,9 pts
A	nimotuzumab	nimotuzumab,chemotherapy (Cisplatin+Etoposide),radiotherapy,9 pts
A	radiotherapy	nimotuzumab,chemotherapy (Cisplatin+Etoposide),radiotherapy,9 pts
the tolerance trial of treatment	nimotuzumab	nimotuzumab,chemotherapy (Cisplatin+Etoposide),radiotherapy,9 pts
the tolerance trial of treatment	Cisplatin	nimotuzumab,chemotherapy (Cisplatin+Etoposide),radiotherapy,9 pts
the tolerance trial of treatment	Etoposide	nimotuzumab,chemotherapy (Cisplatin+Etoposide),radiotherapy,9 pts
A	Cisplatin	nimotuzumab,chemotherapy (Cisplatin+Etoposide),radiotherapy,9 pts
A	Etoposide	nimotuzumab,chemotherapy (Cisplatin+Etoposide),radiotherapy,9 pts
B	Etoposide	chemotherapy (Cisplatin+Etoposide),radiotherapy,9 pts
B	Cisplatin	chemotherapy (Cisplatin+Etoposide),radiotherapy,9 pts

Primary Outcome Measures

Name	Time	Method
Progression-free survival	12months

Secondary Outcome Measures

Name	Time	Method
Overall survival Time	3 years
Quality of life	12 months
Objective response rate	12months
Disease controlled rate	3 years
Adverse event rate	1,2,3,4,5,6,7,8,9,10,11,12,13,14,15,16weeks

Trial Locations

Locations (1)

Cancer Institute & Hospital, Chinese Academy of Medical Sciences; 🇨🇳 Beijing, Beijing, China